---
company: Taysha Gene Therapies, Inc.
ticker: TSHA
form: 8-K
filed: 2026-08-11
accession: 0001193125-26-344594
source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/
---

# Taysha Gene Therapies (TSHA) earnings release, August 11, 2026

Taysha Gene Therapies, Inc. (TSHA) · Form 8-K, Item 2.02 · Filed 2026-08-11 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/)

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating

TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff

Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through

≥

12 months post-TSHA-102, with consistent responses across ages and disease severity

Advanced

TSHA-102 commercial readiness activities, including market access planning initiatives and expansion of strategic partnership with Catalent to support future commercial manufacturing

Completed $230 million follow-on offering, extending cash runway into 2H 2028 and through potential BLA approval of

TSHA-102

Conference call and webcast today at 4:30 PM ET

Dallas – August 11, 2026 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“During the second quarter, we continued to execute against our clinical development strategy for

TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a potential BLA submission,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “The completion of dosing in our REVEAL pivotal and ASPIRE trials, as well as positive longer-term follow-up data from our REVEAL Phase 1/2 trials continues to strengthen our conviction in

TSHA-102 as a potentially transformative therapy for this devastating disease with high unmet need. In addition, the favorable safety profile observed to date across a broad and diverse patient population supports

TSHA-102’s potential to safely deliver durable, meaningful functional benefits.”

Mr. Nolan continued,

“We are working diligently to advance our commercial readiness activities to support the potential launch of

TSHA-102, if approved. Our ongoing market and payer research continues to inform our market access strategy and reinforces

TSHA-102’s significant value proposition and reimbursement potential. We have also expanded our partnership with Catalent, establishing a robust commercial supply framework to support the potential launch of

TSHA-102 and strong demand we expect following potential FDA approval.

Looking ahead, with a strengthened balance sheet, we remain focused on executing our

BLA-enabling activities and anticipate reporting topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.”

Recent Corporate and

TSHA-102

Program Highlights

Anticipated Milestones

Second Quarter 2026 Financial Highlights

Research and

Development Expenses:

Research and development expenses were $38.6 million for the three months ended June 30, 2026, compared to $20.1 million for the three months ended June 30, 2025. The $18.5 million increase was primarily driven by

BLA-enabling

PPQ manufacturing initiatives performed during the three months ended June 30, 2026, and higher clinical expenses from the REVEAL and ASPIRE trials.

Compensation expenses, including non-cash stock-based compensation, also increased as a result of additional research and development headcount.

General and Administrative Expenses:

General and administrative expenses were $12.1 million for the three months ended June 30, 2026, compared to $8.6 million for the three months ended June 30, 2025. The increase of $3.5 million was primarily due to higher compensation expenses, including non-cash stock-based compensation expense, and increases in consulting and professional fees, including commercial launch-readiness initiatives.

Net Loss:

Net loss for the three months ended June 30, 2026, was $46.6 million, or $0.13 per share, compared to a net loss of

$26.9 million, or $0.09 per share, for the three months ended June 30, 2025.

Cash and Cash Equivalents:

As of June 30,

2026, Taysha had $455.4 million in cash and cash equivalents. This reflects the gross proceeds of $230.0 million from the June 2026 follow-on financing, including full exercise of the underwriters’ option to purchase additional shares. The Company expects that its current cash resources will support planned operating expenses and capital requirements into the second half of 2028.

Conference Call and Webcast Information

Taysha management will host a live conference call and webcast today at 4:30 p.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting

Taysha’s website.

About

TSHA-102

TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment,

TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of

MECP2 to cells in the CNS.

TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of

MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.

TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced... (truncated)an Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.

About Rett Syndrome

Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the

X-linked

MECP2 gene encoding methyl

CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic

MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program

TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The

Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as

“anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements.

Forward-looking statements include, but are not limited to, statements concerning the potential of

TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development, regulatory and manufacturing plans for its product candidates, communications with the FDA, including with respect to the BLA for

TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, Taysha’s commercial readiness activities, and the ability of Taysha’s current cash resources to support planned operating expenses into second half of 2028.

Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form

10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and

Taysha disclaims any obligation to update these statements except as may be required by law.

Taysha Gene Therapies, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

Taysha Gene Therapies, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands, except share and per share data)

Company Contact:

Hayleigh Collins

Vice President, Corporate Communications and

Investor Relations

Taysha Gene Therapies, Inc. hcollins@tayshagtx.com

Media Contact:

Media@tayshagtx.com

## Financial statements

### Income Statement (For the Three Months Ended June 30, — (in thousands, except share and per share data))

| | For the Three Months Ended June 30, – 2026 | For the Three Months Ended June 30, – 2025 | For the Six Months Ended June 30, – 2026 | For the Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | $— | 1,986 | $— | 4,288 |
| Operating expenses: | Research and development | 38,636 | 20,141 | 72,445 | 35,706 |
| Operating expenses: | General and administrative | 12,146 | 8,598 | 21,823 | 16,756 |
| Operating expenses: | Net gain on lease termination | -3,433 |  | -3,433 |  |
| Operating expenses: | Total operating expenses | 47,349 | 28,739 | 90,835 | 52,462 |
| Operating expenses: | Loss from operations | -47,349 | -26,753 | -90,835 | -48,174 |
| Other income (expense): | Change in fair value of warrant liability |  | -273 |  | -171 |
| Other income (expense): | Change in fair value of term loan | -1,521 | -1,461 | -2,991 | -2,991 |
| Other income (expense): | Interest income | 2,325 | 1,859 | 4,911 | 3,185 |
| Other income (expense): | Interest expense | -6 | -17 | -15 | -36 |
| Other income (expense): | Other expense | -88 | -237 | -119 | -224 |
| Other income (expense): | Total other income (expense), net | 710 | -129 | 1,786 | -237 |
| Other income (expense): | Net loss | -46,639 | -26,882 | -89,049 | -48,411 |
| Other income (expense): | Net loss per common share, basic and diluted | -0.13 | -0.09 | -0.24 | -0.17 |
| Other income (expense): | Weighted average common shares outstanding, basic and diluted | 369,044,040 | 297,988,978 | 367,845,094 | 283,726,888 |

### Balance Sheet (June 30, 2026 — (in thousands, except share and per share data))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 455,407 | 319,767 |
| Current assets: | Restricted cash |  | 449 |
| Current assets: | Prepaid expenses and other current assets | 6,027 | 4,431 |
| Current assets: | Total current assets | 461,434 | 324,647 |
| Current assets: | Restricted cash | 164 | 2,315 |
| Current assets: | Property, plant and equipment, net | 2,412 | 6,736 |
| Current assets: | Operating lease right-of-use assets | 6,317 | 9,439 |
| Current assets: | Other non-current assets | 106 | 183 |
| Current assets: | Total assets | 470,433 | 343,320 |
| Current liabilities: | Accounts payable | 9,164 | 6,275 |
| Current liabilities: | Accrued expenses and other current liabilities | 16,811 | 20,277 |
| Current liabilities: | Total current liabilities | 25,975 | 26,552 |
| Current liabilities: | Term loan, net | 49,260 | 50,106 |
| Current liabilities: | Operating lease liability, net of current portion | 6,291 | 18,172 |
| Current liabilities: | Other non-current liabilities | 1,641 | 1,552 |
| Current liabilities: | Total liabilities | 83,167 | 96,382 |
| Stockholders’ equity | Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 325,302,280 and 285,051,648 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 3 | 3 |
| Stockholders’ equity | Additional paid-in capital | 1,186,843 | 958,427 |
| Stockholders’ equity | Accumulated other comprehensive income (loss) | 769 | -192 |
| Stockholders’ equity | Accumulated deficit | -800,349 | -711,300 |
| Stockholders’ equity | Total stockholders’ equity | 387,266 | 246,938 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 470,433 | 343,320 |
